Treatment algorithm in patients with ovarian cancer
Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemothera...
Gespeichert in:
Veröffentlicht in: | Facts, views & vision in ObGyn views & vision in ObGyn, 2020-10, Vol.12 (3), p.227-239 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 239 |
---|---|
container_issue | 3 |
container_start_page | 227 |
container_title | Facts, views & vision in ObGyn |
container_volume | 12 |
creator | Vergote, I Denys, H De Greve, J Gennigens, C Van De Vijver, K Kerger, J Vuylsteke, P Baurain, J F |
description | Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7580261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2456409487</sourcerecordid><originalsourceid>FETCH-LOGICAL-l240t-89bc1f85c929bf414aa1a1b89262c9291a555fd4cfa24515e0aa22d305196ab13</originalsourceid><addsrcrecordid>eNpVUMtqwzAQNKWlCWl-ofjYi0FaSbZ0KZTQRyDQS3oWa0V2VGQ7le2U_n2VR0u7lx1md2aHvUimkEuecWDkMmLCICOcykky7_t3EkvSAoS6TiaMUWC5KqYJWweLQ2PbIUVfd8EN2yZ1bbrDwUWyTz8jk3Z7DA7b1GBrbLhJrir0vZ2f-yx5e3pcL16y1evzcvGwyjxwMmRSlYZWUhgFqqw45YgUaSkV5HDgKAohqg03FQIXVFiCCLBhRFCVY0nZLLk_-e7GsrEbE_ME9HoXXIPhS3fo9P9J67a67va6EJJAfjBgJwPvbG11F0qn93AUHvHoa41Gl1ZD_JwGAYIeVHfns6H7GG0_6Mb1xnqPre3GXsewOSeKyyKu3v5N-Bvt57_sGwnleE4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2456409487</pqid></control><display><type>article</type><title>Treatment algorithm in patients with ovarian cancer</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Vergote, I ; Denys, H ; De Greve, J ; Gennigens, C ; Van De Vijver, K ; Kerger, J ; Vuylsteke, P ; Baurain, J F</creator><creatorcontrib>Vergote, I ; Denys, H ; De Greve, J ; Gennigens, C ; Van De Vijver, K ; Kerger, J ; Vuylsteke, P ; Baurain, J F</creatorcontrib><description>Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.</description><identifier>ISSN: 2032-0418</identifier><identifier>ISSN: 2684-4230</identifier><identifier>EISSN: 2684-4230</identifier><identifier>PMID: 33123697</identifier><language>eng</language><publisher>Belgium: Universa Press</publisher><subject>Epithelial ovarian cancer ; genetic testing ; Human health sciences ; Oncologie ; oncology ; Sciences de la santé humaine ; targeted agents ; treatment algorithm ; Viewpoint Paper</subject><ispartof>Facts, views & vision in ObGyn, 2020-10, Vol.12 (3), p.227-239</ispartof><rights>Copyright © 2020 Facts, Views & Vision.</rights><rights>Copyright © 2020 Facts, Views & Vision</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580261/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580261/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33123697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vergote, I</creatorcontrib><creatorcontrib>Denys, H</creatorcontrib><creatorcontrib>De Greve, J</creatorcontrib><creatorcontrib>Gennigens, C</creatorcontrib><creatorcontrib>Van De Vijver, K</creatorcontrib><creatorcontrib>Kerger, J</creatorcontrib><creatorcontrib>Vuylsteke, P</creatorcontrib><creatorcontrib>Baurain, J F</creatorcontrib><title>Treatment algorithm in patients with ovarian cancer</title><title>Facts, views & vision in ObGyn</title><addtitle>Facts Views Vis Obgyn</addtitle><description>Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.</description><subject>Epithelial ovarian cancer</subject><subject>genetic testing</subject><subject>Human health sciences</subject><subject>Oncologie</subject><subject>oncology</subject><subject>Sciences de la santé humaine</subject><subject>targeted agents</subject><subject>treatment algorithm</subject><subject>Viewpoint Paper</subject><issn>2032-0418</issn><issn>2684-4230</issn><issn>2684-4230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVUMtqwzAQNKWlCWl-ofjYi0FaSbZ0KZTQRyDQS3oWa0V2VGQ7le2U_n2VR0u7lx1md2aHvUimkEuecWDkMmLCICOcykky7_t3EkvSAoS6TiaMUWC5KqYJWweLQ2PbIUVfd8EN2yZ1bbrDwUWyTz8jk3Z7DA7b1GBrbLhJrir0vZ2f-yx5e3pcL16y1evzcvGwyjxwMmRSlYZWUhgFqqw45YgUaSkV5HDgKAohqg03FQIXVFiCCLBhRFCVY0nZLLk_-e7GsrEbE_ME9HoXXIPhS3fo9P9J67a67va6EJJAfjBgJwPvbG11F0qn93AUHvHoa41Gl1ZD_JwGAYIeVHfns6H7GG0_6Mb1xnqPre3GXsewOSeKyyKu3v5N-Bvt57_sGwnleE4</recordid><startdate>20201008</startdate><enddate>20201008</enddate><creator>Vergote, I</creator><creator>Denys, H</creator><creator>De Greve, J</creator><creator>Gennigens, C</creator><creator>Van De Vijver, K</creator><creator>Kerger, J</creator><creator>Vuylsteke, P</creator><creator>Baurain, J F</creator><general>Universa Press</general><scope>NPM</scope><scope>7X8</scope><scope>Q33</scope><scope>5PM</scope></search><sort><creationdate>20201008</creationdate><title>Treatment algorithm in patients with ovarian cancer</title><author>Vergote, I ; Denys, H ; De Greve, J ; Gennigens, C ; Van De Vijver, K ; Kerger, J ; Vuylsteke, P ; Baurain, J F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-l240t-89bc1f85c929bf414aa1a1b89262c9291a555fd4cfa24515e0aa22d305196ab13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Epithelial ovarian cancer</topic><topic>genetic testing</topic><topic>Human health sciences</topic><topic>Oncologie</topic><topic>oncology</topic><topic>Sciences de la santé humaine</topic><topic>targeted agents</topic><topic>treatment algorithm</topic><topic>Viewpoint Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vergote, I</creatorcontrib><creatorcontrib>Denys, H</creatorcontrib><creatorcontrib>De Greve, J</creatorcontrib><creatorcontrib>Gennigens, C</creatorcontrib><creatorcontrib>Van De Vijver, K</creatorcontrib><creatorcontrib>Kerger, J</creatorcontrib><creatorcontrib>Vuylsteke, P</creatorcontrib><creatorcontrib>Baurain, J F</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Université de Liège - Open Repository and Bibliography (ORBI)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Facts, views & vision in ObGyn</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vergote, I</au><au>Denys, H</au><au>De Greve, J</au><au>Gennigens, C</au><au>Van De Vijver, K</au><au>Kerger, J</au><au>Vuylsteke, P</au><au>Baurain, J F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment algorithm in patients with ovarian cancer</atitle><jtitle>Facts, views & vision in ObGyn</jtitle><addtitle>Facts Views Vis Obgyn</addtitle><date>2020-10-08</date><risdate>2020</risdate><volume>12</volume><issue>3</issue><spage>227</spage><epage>239</epage><pages>227-239</pages><issn>2032-0418</issn><issn>2684-4230</issn><eissn>2684-4230</eissn><abstract>Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.</abstract><cop>Belgium</cop><pub>Universa Press</pub><pmid>33123697</pmid><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2032-0418 |
ispartof | Facts, views & vision in ObGyn, 2020-10, Vol.12 (3), p.227-239 |
issn | 2032-0418 2684-4230 2684-4230 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7580261 |
source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Epithelial ovarian cancer genetic testing Human health sciences Oncologie oncology Sciences de la santé humaine targeted agents treatment algorithm Viewpoint Paper |
title | Treatment algorithm in patients with ovarian cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A09%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20algorithm%20in%20patients%20with%20ovarian%20cancer&rft.jtitle=Facts,%20views%20&%20vision%20in%20ObGyn&rft.au=Vergote,%20I&rft.date=2020-10-08&rft.volume=12&rft.issue=3&rft.spage=227&rft.epage=239&rft.pages=227-239&rft.issn=2032-0418&rft.eissn=2684-4230&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2456409487%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2456409487&rft_id=info:pmid/33123697&rfr_iscdi=true |